Pacific Biosciences
PACB
226 hedge funds and large institutions have $475M invested in Pacific Biosciences in 2024 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 75 increasing their positions, 65 reducing their positions, and 35 closing their positions.
64% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $4.17M
20% more capital invested
Capital invested by funds: $395M → $475M (+$80.5M)
15% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 65
11% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 35
9.67% more ownership
Funds ownership: 85.1% → 94.77% (+9.7%)
0% more funds holding
Funds holding: 226 → 226 (0)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SoftBank Group
Tokyo,
Japan
|
+$39.9M |
| 2 |
Millennium Management
New York
|
+$13M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$9.56M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.15M |
| 5 |
Morgan Stanley
New York
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$5.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.72M |
| 3 |
Jane Street
New York
|
-$4.38M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$4.04M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$3.29M |
PACB Hedge Fund Activity: Q4 2024 in Review
226 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2024, worth a combined $475M — up 20% from $395M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new PACB positions and 35 closed out — a net gain of 4 holders — while 75 added to existing stakes and 65 trimmed.
The largest buyer was SoftBank Group, opening a new position worth an estimated $39.9M. The largest seller was Capital World Investors, exiting entirely with an estimated $5.76M sold.
- 226 institutional investors held Pacific Biosciences (PACB) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $475M of Pacific Biosciences stock for Q4 2024, up 20% quarter-over-quarter.
- 39 funds opened new Pacific Biosciences positions in Q4 2024 and 35 closed out, a net change of +4 holders.
- The largest Pacific Biosciences buyer in Q4 2024 was SoftBank Group, an estimated $39.9M added.
- The largest Pacific Biosciences seller in Q4 2024 was Capital World Investors, an estimated $5.76M sold.
Based on aggregated 13F filings for Q4 2024.